Adalimumab effectiveness in COVID-19
- Conditions
- COVID-19.C0VID-19U07.1
- Registration Number
- IRCT20150303021315N22
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Patients with the ability to comprehend and willingness to participate in the trial?.
Patients who are at least 18 years old at the beginning of trial.
Patients with Fever higher than 37.8 C, Cough, shortness of breath accompanied by SpO2 =%93, who ?have a confirmed diagnosis of SARS-CoV-2 infection using RT-PCR.
patients with increased level of TNF-alpha to 3 times as much as normal range or with remarkable increase in CRP or Ferritin.
Patients attending other clinical trials at the same time.
patients who are pregnant or breastfeeding.
patients with (ALT/AST> 5ULN, ANC <0.5 (x109/L), Platelet count<50 (x109/L) based on laboratory findings.
People with active immune-related rheumatic diseases who have been treated with anti-TNF medications for the last 6 months.
People taking immunosuppressive drugs.
People who are allergic to adalimumab or other components of the formulation of these drugs.
People with active pulmonary tuberculosis or other active bacterial or fungal infections (Based on IGRA, procalcitonin and blood culture)
People with heart failure (grades 3 and 4 of NYHA).
History of demyelinating diseases in the patient or his/her family
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method